These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35683580)

  • 1. Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study.
    Tillmann FP; Figiel L; Ricken J; Still H; Korte C; Plaßmann G; Harth A; Jörres A; von Landenberg P
    J Clin Med; 2022 Jun; 11(11):. PubMed ID: 35683580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study.
    Tillmann FP; Figiel L; Ricken J; Still H; Korte C; Plassmann G; von Landenberg P
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
    Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Schirripa M; Signorelli C; Chilelli MG; Primi F; Pessina G; Natoni F; Silvestri MA; Ruggeri EM
    Curr Oncol; 2023 May; 30(5):5103-5115. PubMed ID: 37232844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster.
    Zhao J; Zhang H; Jiang L; Cheng F; Li W; Wang Z; Liu H; Li S; Jiang Y; Li M; Li Y; Liu S; Fang M; Zhou X; Ye X; Zhao S; Zheng Y; Meng S
    Microbiol Spectr; 2024 Mar; 12(3):e0243523. PubMed ID: 38319108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 Vaccine.
    Liao BH; Platen L; Grommes M; Cheng CC; Holzmann-Littig C; Christa C; Haller B; Kappler V; Bester R; Werz ML; Platen E; Eggerer P; Tréguer L; Küchle C; Schmaderer C; Heemann U; Renders L; Protzer U; Braunisch MC
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
    Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D;
    J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term trajectories of SARS-CoV-2 neutralizing antibodies and predictive value of first dose vaccination-induced IgG-antibodies in hemodialysis patients.
    Tillmann FP; Still H; von Landenberg P
    Int Urol Nephrol; 2022 Aug; 54(8):1939-1945. PubMed ID: 34860338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
    Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
    Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.
    Hofsink Q; Haggenburg S; Lissenberg-Witte BI; Broers AEC; van Doesum JA; van Binnendijk RS; den Hartog G; Bhoekhan MS; Haverkate NJE; van Meerloo J; Burger JA; Bouhuijs JH; Smits GP; Wouters D; van Leeuwen EMM; Bontkes HJ; Kootstra NA; Vogels-Nooijen S; Rots N; van Beek J; Heemskerk MHM; Groen K; van Meerten T; Mutsaers PGNJ; van Gils MJ; Goorhuis A; Rutten CE; Hazenberg MD; Nijhof IS;
    EClinicalMedicine; 2023 Jul; 61():102040. PubMed ID: 37337616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Antibody Titers after SARS-CoV-2 Vaccination-Insights from Self-Paid Tests at a General Internal Medicine Clinic.
    Kusunoki H; Ekawa K; Ekawa M; Kato N; Yamasaki K; Motone M; Shimizu H
    Medicines (Basel); 2023 Apr; 10(4):. PubMed ID: 37103782
    [No Abstract]   [Full Text] [Related]  

  • 12. Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
    Wei J; Matthews PC; Stoesser N; Newton JN; Diamond I; Studley R; Taylor N; Bell JI; Farrar J; Kolenchery J; Marsden BD; Hoosdally S; Jones EY; Stuart DI; Crook DW; Peto TEA; Walker AS; Pouwels KB; Eyre DW;
    Nat Commun; 2023 May; 14(1):2799. PubMed ID: 37193713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individuals With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough Infections.
    Möhlendick B; Čiučiulkaitė I; Elsner C; Anastasiou OE; Trilling M; Wagner B; Zwanziger D; Jöckel KH; Dittmer U; Siffert W
    Front Immunol; 2022; 13():907343. PubMed ID: 35812411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immune response as an indicator for protection against Covid-19 after anti-SARS-COV2-booster vaccination in hematological and oncological patients.
    Mainka D; Bauer N; Dietze L; Lehnert S; Krandick J; Himmelreich D; Jomaa H; Zimmermann M; Borchmann P; Herbrandt S; Rothe A
    Int J Cancer; 2024 Dec; 155(12):2141-2148. PubMed ID: 39222267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.
    Bruel T; Pinaud L; Tondeur L; Planas D; Staropoli I; Porrot F; Guivel-Benhassine F; Attia M; Pelleau S; Woudenberg T; Duru C; Koffi AD; Castelain S; Fernandes-Pellerin S; Jolly N; De Facci LP; Roux E; Ungeheuer MN; Van Der Werf S; White M; Schwartz O; Fontanet A
    EClinicalMedicine; 2022 Sep; 51():101576. PubMed ID: 35891947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination.
    Hein S; Mhedhbi I; Zahn T; Sabino C; Benz NI; Husria Y; Renelt PM; Braun F; Oberle D; Maier TJ; Hildt C; Hildt E
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab.
    Ziemssen T; Groth M; Ettle B; Bopp T
    Hum Vaccin Immunother; 2024 Dec; 20(1):2316422. PubMed ID: 38346223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario.
    Krekeler C; Reitnauer L; Bacher U; Khandanpour C; Steger L; Boeckel GR; Klosner J; Tepasse PR; Kemper M; Hennies MT; Mesters R; Stelljes M; Schmitz N; Kerkhoff A; Schliemann C; Mikesch JH; Schmidt N; Lenz G; Bleckmann A; Shumilov E
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS-CoV-2 Omicron in patients with haematological malignancies: A national prospective cohort study.
    Kevličius L; Šablauskas K; Maneikis K; Juozapaitė D; Ringelevičiūtė U; Vaitekėnaitė V; Davainienė B; Daukėlaitė G; Vasilevska D; Stoškus M; Narkevičiūtė I; Sivickienė V; Rudaitis K; Minkauskas M; Naumovas D; Beinortas T; Griškevičius L
    Br J Haematol; 2024 Feb; 204(2):497-506. PubMed ID: 37786970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term observation of antibody titers against SARS-CoV-2 following vaccination.
    Sugiyama K; Suzuki C; Aoyama M; Toyota N; Nakagawa N; Shozu M; Nakai K; Iwano K
    Public Health Pract (Oxf); 2022 Dec; 4():100297. PubMed ID: 35847239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.